Journal
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 12, Issue 5A, Pages 1426-1431Publisher
WILEY
DOI: 10.1111/j.1582-4934.2008.00398.x
Keywords
miR-210; hypoxia; cancer; ischemia; microRNAs; HIF
Categories
Funding
- Elsa Pardee Foundation Award
- AACR/PanCancareer development award
- NIH [P30 DK-34928]
- Cancer Research UK
- Ministero della Salute [RC06/07-1.13, RF05-Conv.79.1, RF05-ISS 64D/F4, RF06-Conv.74.1, RF07Onc-26/1, RO.06-M.-conv.29/07-1]
Ask authors/readers for more resources
MicroRNAs (miRs) are short non-coding transcripts involved in a wide variety of cellular processes. Several recent studies have established a link between hypoxia, a well-documented component of the tumour microenvironment, and specific miRs. One member of this class, miR-210, was identified as hypoxia inducible in all the cell types tested, and is overexpressed in most cancer types. Its hypoxic induction is dependent on a functional hypoxia-inducible factor (HIF), thus extending the transcriptional repertoire of the latter beyond 'classic' genes. From a clinical standpoint, miR-210 overexpression has been associated with adverse prognosis in breast tumours and been detected in serum of lymphoma patients and could serve as a tool to define hypoxic malignancies. We discuss the role of miR-210 and its emerging targets, as well as possible future directions for clinical applications in oncology and ischaemic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available